Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scaling-Up Research in Childhood Cancer in Low- and Middle-Income Countries.

Pediatric blood & cancer·2026
Same author

Challenges in Launching a Precision Pediatric Oncology Program in Argentina.

Pediatric blood & cancer·2026
Same author

Challenges for Early Diagnosis in Retinoblastoma in Low- and Middle-Income Countries.

Pediatric blood & cancer·2025
Same author

A Retrospective Cohort Analysis of Children and Adolescents With Lymphoblastic Lymphoma in Latin America.

Pediatric blood & cancer·2025
Same author

Strengthening the paediatric clinical trial ecosystem to better inform policy and programmes.

The Lancet. Global health·2025
Same author

Safety Assessment of Aqueous Humor Liquid Biopsy in Retinoblastoma: A Multicenter Study of 1203 Procedures.

Ophthalmology·2025

Related Experiment Video

Updated: May 30, 2026

Reconstruct Human Retinoblastoma In Vitro
06:52

Reconstruct Human Retinoblastoma In Vitro

Published on: October 11, 2022

Retinoblastoma: lessons and challenges from developing countries. Ellsworth Lecture 2011.

Guillermo L Chantada1

  • 1Hemato-oncology Department, Hospital JP Garrahan, Buenos Aires, Argentina. gchantada@yahoo.com

Ophthalmic Genetics
|July 21, 2011
PubMed
Summary

Retinoblastoma survival rates are lower in developing nations due to late diagnosis and limited treatment access. Improving socioeconomic factors and treatment adherence is crucial for better patient outcomes in these regions.

More Related Videos

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
07:55

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice

Published on: August 4, 2011

Related Experiment Videos

Last Updated: May 30, 2026

Reconstruct Human Retinoblastoma In Vitro
06:52

Reconstruct Human Retinoblastoma In Vitro

Published on: October 11, 2022

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
07:55

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice

Published on: August 4, 2011

Area of Science:

  • Ophthalmology
  • Pediatric Oncology
  • Global Health

Background:

  • Retinoblastoma survival rates significantly differ between developed and developing countries.
  • Key factors contributing to poor outcomes include delayed diagnosis, inadequate treatment adherence, and resource limitations.
  • Socioeconomic indicators correlate with patient survival chances and treatment compliance.

Purpose of the Study:

  • To review the challenges affecting retinoblastoma patient survival in developing countries.
  • To explore the association between socioeconomic development and treatment outcomes.
  • To identify strategies for improving retinoblastoma care and survival rates globally.

Main Methods:

  • Literature review of studies on retinoblastoma in developing countries.
  • Analysis of socioeconomic factors influencing diagnosis and treatment.
  • Synthesis of evidence on treatment adherence and outcomes.

Main Results:

  • Developing countries face significant hurdles in retinoblastoma management.
  • Late diagnosis is a primary driver of reduced survival.
  • Socioeconomic status directly impacts access to timely and effective treatment.

Conclusions:

  • Addressing socioeconomic disparities is essential for improving retinoblastoma survival.
  • Enhancing treatment compliance and overcoming resource limitations are critical.
  • Implementing targeted strategies can lead to better outcomes for retinoblastoma patients worldwide.